Dermatology
Latest News
VEXAS Syndrome: Study Highlights Cutaneous Symptoms
Affected individuals exhibit a wide range of manifestations, including cytopenia/myelodysplasia, multiorgan systemic inflammation, and cutaneous...
Opinion
Pruritic, violaceous papules in a patient with renal cell carcinoma
Pembrolizumab was discontinued by oncology because the patient had completed a majority of the cycles of therapy.
Latest News
Photoprotection: Benefits of Sunscreens With Iron Oxide
When blended with mineral sunscreens, iron oxide can reduce transmission of visible light by 90% and can protect patients from hyperpigmentation...
Pediatric Dermatology Consult
A 7-year-old female presents with persistent pimples on the nose and cheeks for approximately 1 year
A 7-year-old female presents with persistent pimples on the nose and cheeks.
Latest News
Cosmetic Tattoo Ingredients Associated With Contact Dermatitis
Permanent makeup is becoming more popular, and there have been reports of ACD related to pigments contained in the inks.
Latest News
Study Highlights Melanoma Survival Disparities in Rural vs Urban Settings
To characterize the rural population diagnosed with melanoma and assess associated disparities in the United States, researchers used data from...
Latest News
Features of Merkel Cell in Hispanic Patients Explored
The incidence of Merkel cell carcinoma is increasing among all racial groups, especially in the Hispanic population.
Latest News
Study Finds Isotretinoin Effective for Acne in Transgender Patients on Hormone Rx
While isotretinoin is an effective treatment option for acne, its effectiveness and safety in transgender and gender-diverse individuals are not...
Latest News
Hidradenitis Suppurativa: Clinical Outcomes for Bimekizumab Positive in Phase 3 Studies
The primary outcome was an HS clinical response of at least 50% at week 16, defined as at least a 50% reduction in total abscess and inflammatory...
From the Journals
Clear Coverage Preference for Humira Over Biosimilars Seen in Most Medicare Part D Plans
This narrow coverage limits the cost-saving potential of these biosimilar competitors, the authors of a new study said.
News from the FDA/CDC
FDA Grants New Pediatric Arthritis Indications for Upadacitinib
The JAK inhibitor’s safety profile for patients as young as 2 years was similar to the known safety profile in adults.